Synthetic Approaches To The New Drugs 2017
➤ Gửi thông báo lỗi ⚠️ Báo cáo tài liệu vi phạmNội dung chi tiết: Synthetic Approaches To The New Drugs 2017
Synthetic Approaches To The New Drugs 2017
Journal ofMedicinal Chemistryc> Gte This: J. Mix). Chtm. 2019.62. 7340-7382pubxacsxicg.’jmcSynthetic Approaches to the New Drugs Approved During 2017A Synthetic Approaches To The New Drugs 2017 Andrew c. Flick, ,J Carolyn A. Leverett/’* Hong X. Dinc/’v Emma Mclnturff/0 Sarah J. Fink, Christopher J. Helal/ 1 and Christopher J. O'Donnell**’Seattle Genetics, Inc. 21823 30th Drive SE, Bothell, Washington 98021, United States^Groton laboratories, Pfizer Worldwide Research anil Development, -1'1 Synthetic Approaches To The New Drugs 2017 $ Eastern Point Road, Groton, Connecticut 116.3-10, United StatesSynthetic Approaches To The New Drugs 2017
oad. San Diego, California 92121, United StatesDown ..kJvia INIVFRAKK Isil.2"■ 3.131 I Cl'll I p--7p.l>s Ự-Kự-I >14. I l.:| I.:- ĩ<- ‘li I - ■■ 11 >.»Journal ofMedicinal Chemistryc> Gte This: J. Mix). Chtm. 2019.62. 7340-7382pubxacsxicg.’jmcSynthetic Approaches to the New Drugs Approved During 2017A Synthetic Approaches To The New Drugs 2017 Mid XVPlus Bw 30 ww Oxo-I rrarw«c n 2017ABSTRACT: New drugs introduced tn the market every year represent privileged structures for particular biological targets. These new chemical entities (NCI-s) provide insight into molecular recognition while .serving as leads for designing future new drugs. 'I Synthetic Approaches To The New Drugs 2017 llis annual review describes the most likely proie.ss scale synthetic approaches to '31 new chemical entities approved for the first time globally inSynthetic Approaches To The New Drugs 2017
2017.1. INTRODUCTION'I hr. most fruitful hosts for íỉư discovery Ilf a new drug is ill start with an old drug.'Sir James Whyte Black, Winner nt' the 1Journal ofMedicinal Chemistryc> Gte This: J. Mix). Chtm. 2019.62. 7340-7382pubxacsxicg.’jmcSynthetic Approaches to the New Drugs Approved During 2017A Synthetic Approaches To The New Drugs 2017 new chemical entities and approaches to their construction will enhance the ability to discover new drugs more efficiently. This annual review, which IS now in its 17th installment,* presents synthetic routes for 31 new molecular entities tint were approved for the first time by a governing body an Synthetic Approaches To The New Drugs 2017 ywhere in the world during the 2017 calendar year (Figure l). For each drug, a description of the most likely process scale synthetic approach, or inSynthetic Approaches To The New Drugs 2017
some cases the only publicly disclosed synthetic approach, IS prefaced by a brief introduction summarizing the relevant pharmacology or differentiatinJournal ofMedicinal Chemistryc> Gte This: J. Mix). Chtm. 2019.62. 7340-7382pubxacsxicg.’jmcSynthetic Approaches to the New Drugs Approved During 2017A Synthetic Approaches To The New Drugs 2017 eviously launched medications, new combinations or formulations of existing drugs, and drugs synthesized entirely by biological processes or peptide synthesizers have been excluded from coverage. For organizational purposes, drugs presented in this review arc categorized into the following eight the Synthetic Approaches To The New Drugs 2017 rapeutic areas: anti-mfeclive, CNS (neuroscience), gastrointestinal, hematologic, metabolic, musculoskeletal, oncology, and ophthalmology. Within eachSynthetic Approaches To The New Drugs 2017
of these therapeutic areas, dnigs are ordered alphabetically by generic name. It is important to note that a drugs process-scalesynthetic approach isJournal ofMedicinal Chemistryc> Gte This: J. Mix). Chtm. 2019.62. 7340-7382pubxacsxicg.’jmcSynthetic Approaches to the New Drugs Approved During 2017A Synthetic Approaches To The New Drugs 2017 of delivering the active pharmaceutical ingredient (API) has been made available. Nonetheless, foe synthetic sequences presented in this review have all been previously reported either in patent or public chemical literature and, to the best of our assessment, represent scalable routes originating Synthetic Approaches To The New Drugs 2017 from commercially available .starting materials (determined by explicit .statement or inferred by experimental detail).2. ANTI-INFECTIVE DRUGS2.1.AmenSynthetic Approaches To The New Drugs 2017
amevir (Amenalief). Originally discovered by Astellas and codevelopcd with Maniho Co., I .td., amenamevir IS an antiviral agent approved for the firstJournal ofMedicinal Chemistryc> Gte This: J. Mix). Chtm. 2019.62. 7340-7382pubxacsxicg.’jmcSynthetic Approaches to the New Drugs Approved During 2017A Synthetic Approaches To The New Drugs 2017 kinetic profile over existing therapies acyclovir and valacydovir." Researchers from Astellas attribute amenamevir’s differentiated profile to an improved absorption ratio (not hepatic availability) and slower rates of metabolism relative to acydovir/valacyclovir. Perhaps unsurprisingly, the primary Synthetic Approaches To The New Drugs 2017 metabolic pathway in rodents involves oxidation of the methyl groups affixed to the central aniline ring along with conversion of the oxadiazolc to tSynthetic Approaches To The New Drugs 2017
he corresponding amidine residue? The half-life of the drug in human plasma was found to be 8 h, which translates into a once-daily dosing regimen,RecJournal ofMedicinal Chemistryc> Gte This: J. Mix). Chtm. 2019.62. 7340-7382pubxacsxicg.’jmcSynthetic Approaches to the New Drugs Approved During 2017A Synthetic Approaches To The New Drugs 2017 ournal of Medicinal ChemistryPerspectiveAnti-lnfeclive Pftxi»Amenamevlr IIIBenznidazole (IQOlafloxacin meglumine (llllJournal ofMedicinal Chemistryc> Gte This: J. Mix). Chtm. 2019.62. 7340-7382pubxacsxicg.’jmcSynthetic Approaches to the New Drugs Approved During 2017AGọi ngay
Chat zalo
Facebook